Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Immune checkpoint inhibitors don’t increase risk of death in cancer patients with COVID-19

Key clinical point: Treatment with immune checkpoint inhibitors does not appear to increase mortality risk among cancer patients with COVID-19.

Major finding: The mortality rate was 8% in patients with cancer and COVID-19 who received immune checkpoint inhibitors, which is comparable with the overall mortality rate previously reported among cancer patients with COVID-19 (7.6%-12%).

Study details: A study of 113 patients with COVID-19 and cancer in Europe, North America, and Australia.

Disclosures: Dr. Rogiers reported having no conflicts of interest. There was no funding disclosed for the study.


Rogiers A et al. AACR: COVID-19 and Cancer, Abstract S02-01.